N
Nicola P. Klein
Researcher at Kaiser Permanente
Publications - 292
Citations - 10778
Nicola P. Klein is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 44, co-authored 234 publications receiving 6652 citations. Previous affiliations of Nicola P. Klein include Marshfield Clinic.
Papers
More filters
Journal ArticleDOI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David K. C. Cooper,Timothy Jennings,Donald M Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of.
Journal ArticleDOI
Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children
TL;DR: Pertussis waned during the 5 years after the fifth dose of DTaP, and the odds of acquiring pertussis increased by an average of 42% per year after 2006 to 2011.
Journal ArticleDOI
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Nicola P. Klein,Ned Lewis,Kristin Goddard,Bruce Fireman,Ousseny Zerbo,Kayla E. Hanson,James G. Donahue,Elyse O. Kharbanda,Allison L. Naleway,Jennifer C. Nelson,Stan Xu,W. Katherine Yih,Jason M. Glanz,Jason M. Glanz,Joshua T B Williams,Simon J. Hambidge,Bruno Lewin,Tom T. Shimabukuro,Frank DeStefano,Eric Weintraub +19 more
TL;DR: In this article, the authors present an interim analysis of safety surveillance data from Vaccine Safety Datalink for COVID-19 vaccination, with a risk interval of 21 days for individuals after either vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 2 or 3.
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety
James Baggs,Julianne Gee,Edwin Lewis,Gabrielle Fowler,Patti Benson,Tracy A. Lieu,Allison L. Naleway,Nicola P. Klein,Roger Baxter,Edward A. Belongia,Jason M. Glanz,Simon J. Hambidge,Steven J. Jacobsen,Lisa A. Jackson,Jim Nordin,Eric Weintraub +15 more
TL;DR: With its recent enhancements, the VSD provides scientific expertise, continues to develop innovative approaches for vaccine-safety research, and may serve as a model for other patient safety collaborative research projects.